Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment Patterns and Survival Outcomes in a Real-World Cohort of 263 Patients with EGFR L858R-Mutant Non-Small Cell Lung Cancer: Focus on EGFR-TKI Selection.

Asian Pacific journal of cancer prevention : APJCP - 1 Jul 2026

Pham Vinh Hung, Do Huyen Nga, Nguyen Khanh Toan, Ngo Lam Van, Pham Thi Huong, Vo Thi Hong Anh, Phan Thi Thuy, Tran Thi Thu Hien, Tran Thi My Hanh, Nguyen Thi Thuy My, Le Van Thanh, Le Thi Hai Yen, Tran Tuan Trung, Truong Khanh Hung

Abstract excerpt

AIM: Compare the treatment efficacy of EGFR TKIs in patients with non-small cell lung cancer with the EGFR L858R exon 21 mutation. MATERIALS AND METHODS: This retrospective analysis included 263 patients with advanced non-small cell lung cancer harboring the EGFR L858R mutation who were treated with EGFR tyrosine kinase inhibitors (TKIs) at Nghe An Oncology Hospital, Vietnam, between January 2018 and June 2025....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Survival Rate

Source

Identifiers

PMID: 42522829
DOI: 10.31557/APJCP.2026.27.7.2673

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment Patterns and Survival Outcomes in a Real-World Cohort of 263 Patients with EGFR L858R-Mutant Non-Small Cell Lung Cancer: Focus on EGFR-TKI Selection.PMID 42522829Read ↗

Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.Semantic proximity Read ↗

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.Semantic proximity Read ↗

Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study.Semantic proximity Read ↗

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.Semantic proximity Read ↗

Clinical Outcomes of Epidermal Growth Factor Receptor (EGFR) Mutated Metastatic Non-Small Cell Lung Cancer in Kurdistan Region: A Retrospective StudySemantic proximity Read ↗

Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT).Semantic proximity Read ↗

Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.Semantic proximity Read ↗

Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.Semantic proximity Read ↗

Efficacy and safety of first-line treatments for patients with advanced epidermal growth factor receptor mutated non-small cell lung cancer: a network meta- analysisSemantic proximity Read ↗

Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).Semantic proximity Read ↗

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.